Literature DB >> 10066664

Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis.

J M Wolter1, R L Rodwell, S D Bowler, J G McCormack.   

Abstract

Various treatment regimens and difficulties with research design are encountered with cystic fibrosis (CF) because no standard diagnostic criteria exist for defining acute respiratory exacerbations. This study evaluated the role of serial monitoring of concentrations of selected cytokines and inflammatory mediators in serum and sputum as predictors of respiratory exacerbation, as useful outcome measures for CF, and to guide therapy. Interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-alpha), neutrophil elastase-alpha-1-protease inhibitor complex (NE complex), protein, and alpha-1-protease inhibitor (alpha-1-PI) were measured in serum and sputum collected from CF patients during respiratory exacerbations and periods of well-being. Levels of NE complex, protein, and alpha-1-PI in sputum rose during respiratory exacerbations and fell after institution of antibiotic therapy (P = 0.078, 0.001, and 0.002, respectively). Mean (+/- standard error of the mean) levels of IL-8 and TNF-alpha were extremely high in sputum (13,780 +/- 916 and 249.4 +/- 23.5 ng/liter, respectively) but did not change significantly with clinical deterioration of the patient (P > 0.23). IL-8 and TNF-alpha were generally undetectable in serum, and therefore these measures were unhelpful. Drop in forced expiratory volume in 1 s was the only clinical or laboratory parameter that was close to being a determinant of respiratory exacerbation (P = 0.055). This study provides evidence of intense immunological activity occurring continually within the lungs of adult CF patients. Measurement of cytokines and inflammatory mediators in CF sputum is not helpful for identifying acute respiratory exacerbations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066664      PMCID: PMC95697          DOI: 10.1128/CDLI.6.2.260-265.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

Review 1.  The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1.

Authors:  R M Strieter; A E Koch; V B Antony; R B Fick; T J Standiford; S L Kunkel
Journal:  J Lab Clin Med       Date:  1994-02

2.  The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.

Authors:  J S Elborn; S M Cordon; D Parker; F M Delamere; D J Shale
Journal:  Respir Med       Date:  1993-11       Impact factor: 3.415

3.  Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs.

Authors:  G Kronborg; M B Hansen; M Svenson; A Fomsgaard; N Høiby; K Bendtzen
Journal:  Pediatr Pulmonol       Date:  1993-05

4.  Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis.

Authors:  J S Elborn; S M Cordon; D J Shale
Journal:  Pediatr Pulmonol       Date:  1993-05

5.  Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis.

Authors:  T P Dean; Y Dai; J K Shute; M K Church; J O Warner
Journal:  Pediatr Res       Date:  1993-08       Impact factor: 3.756

6.  Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J W Mouton; J G den Hollander; A M Horrevorts
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

7.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

Authors:  M W Konstan; K A Hilliard; T M Norvell; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

8.  alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis.

Authors:  C M O'Connor; K Gaffney; J Keane; A Southey; N Byrne; S O'Mahoney; M X Fitzgerald
Journal:  Am Rev Respir Dis       Date:  1993-12

9.  Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.

Authors:  P Greally; M J Hussein; A J Cook; A P Sampson; P J Piper; J F Price
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

10.  Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.

Authors:  A L Smith; G Redding; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; T Rubio
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

View more
  14 in total

1.  Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men.

Authors:  Raghu Sinha; Indu Sinha; Nicole Facompre; Stephen Russell; Richard I Somiari; John P Richie; Karam El-Bayoumy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-19       Impact factor: 4.254

Review 2.  Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Authors:  Maaike Cockx; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 3.  Pathogenesis and management of nasal polyposis in cystic fibrosis.

Authors:  Jochen G Mainz; Assen Koitschev
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 4.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

Review 5.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

7.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

Review 8.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

9.  Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease.

Authors:  Milene T Saavedra; Grant J Hughes; Linda A Sanders; Michelle Carr; David M Rodman; Christopher D Coldren; Mark W Geraci; Scott D Sagel; Frank J Accurso; James West; Jerry A Nick
Journal:  Am J Respir Crit Care Med       Date:  2008-08-21       Impact factor: 21.405

10.  Isolation and characterization of microparticles in sputum from cystic fibrosis patients.

Authors:  Chiara Porro; Silvia Lepore; Teresa Trotta; Stefano Castellani; Luigi Ratclif; Anna Battaglino; Sante Di Gioia; Maria C Martínez; Massimo Conese; Angela B Maffione
Journal:  Respir Res       Date:  2010-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.